Objective
To evaluate patient experience of Basal-IQ® technology during real-world use. While the patient experience scores reported in clinical trials are important, real-world use provides enhanced data insights to estimate ongoing sustainability and usefulness of diabetes technologies.
Method
In May 2019, users of the t:slim X2™ insulin pump with Basal-IQ technology voluntarily responded to an online survey via Qualtrics, an online survey software. Nine metrics measured satisfaction, trust, usability, and utility of the system on a 5-point Likert scale.
Results
Participants reported high levels of satisfaction, trust, and overall usability. Survey findings showed that users perceived that the system has helped improved their sleep and overall blood glucose control. Results did not vary by age or prior therapy.
Conclusion
Study findings supported a very positive real-world experience of Basal-IQ technology in a large sample of users. Patient satisfaction with diabetes device technology has shown to be a critical factor in successful long-term diabetes management.
Product Documentation
Consult user guides for our pumps, infusion sets, predictive technology, and reporting app.
View DocumentationProduct Training
Use our education tutorials to train your patients or CDEs on our easy-to-use products.
View ResourcesRecommending
Recommending the t:slim X2 insulin pump is easy with our customized referral process and insurance benefits check.
Learn More
Responsible Use of Basal-IQ Technology
References:
1. Forlenza GP, Li Z, Buckingham BA, et al. Predictive low-glucose suspend reduces
hypoglycemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized
crossover study: Results of the PROLOG trial. Diabetes Care. 2018;41(10):2155-2161.
2. Tanenbaum ML,
IturraldeE, Hanes SJ, et al. Trust in hybrid closed loop among people with diabetes: perspectives of
experienced system users. J Health Psychol. doi:10.1177/1359105317718615.
3. Weissberg-Benchell J,
Hood K, LaffelL, et al. Toward development of psychosocial measures for automated insulin delivery.
J Diabetes Sci Technol. 2016;10(3):799-801.
4. Farrington C. Psychosocial impacts of hybrid closed-loop
systems in the management of diabetes: a review. DiabetMed. 2018;35(4), 436-449.
Important Safety Information
The t:slim X2 insulin pump with Basal-IQ technology (the System) consists of the t:slim X2 insulin pump, which contains Basal-IQ technology, and a compatible continuous glucose monitor (CGM, sold separately). The t:slim X2 insulin pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The t:slim X2 insulin pump can be used solely for continuous insulin delivery and as part of the System. When used with a compatible CGM, the System can be used to suspend insulin delivery based on CGM sensor readings. The pump and the System are indicated for use in individuals six years of age and greater. The pump and the System are intended for single user use. The pump and the System are indicated for use with NovoRapid, Admelog, or Humalog U-100 insulin. The System is not indicated for use in pregnant women, people on dialysis, or critically ill users. Users of the pump and the System must: be willing and able to use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts. The t:slim X2 pump and the CGM transmitter and sensor must be removed before MRI, CT, or diathermy treatment. Visit tandemdiabetes.com/safetyinfo for additional important safety information.